Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies.

Monte Rosa Therapeutics

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.

RTW Investments

Cormorant Asset Management

Fidelity

Google Ventures

New Enterprise Associates

Cambridge Asset Management

Casdin Capital

HBM Healthcare Investments AG

Fidelity Management and Research Company

Aisling Capital

Amzak Health Investors

Avoro Capital Advisors

Today we share our second quarter 2024 financial results and corporate update. View the full press release here: https://bit.ly/3WDjih9

Step into the future with Monte Rosa's dynamic Data Sciences team! #DataSciences #AI #Biotech

We’re pleased to share this brand new scientific review of VAV1 published in Trends in Immunology, highlighting the therapeutic potential of novel approaches targeting VAV1 for autoimmune diseases, including our VAV1 molecular glue degrader MRT-6160. 

Read the scientific review here: https://bit.ly/4c6BO6Z

Every year Monte Rosa welcomes the brilliant scientists of tomorrow. Their curiosity, innovation, and enthusiasm help shape our culture. Learn more about the Monte Rosa Internship experience. #NationalInternDay #Biotech

Starting off the summer with good times and great people. 
#Summer #GoodTimes

Join our CEO Markus Warmuth next week for a fireside chat at the virtual UBS TPD day. Learn more here: https://bit.ly/3zuVS5I

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	3.19M -	7.07M 121.16%	6.56M 7.19%	7.86M 19.88%	11.15M 41.85%
accumulated other comprehensive income loss		-1.06M -	-2.02M 91.38%	-1.75M 13.31%	-2.72M 55.48%
cash and cash equivalents	6.00M -	41.70M 595.56%	346.07M 729.93%	54.91M 84.13%	128.10M 133.28%
cash and short term investments	6.00M -	41.70M 595.56%	346.07M 729.93%	262.83M 24.05%	232.41M 11.57%
common stock	50K -	1K 98%	5K 400%	5K 0%	5K 0%
deferred revenue					17.68M -
deferred revenue non current					32.32M -
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory				960K -
long term debt				43.87M -	42.88M 2.27%
long term investments					4.58M -
net debt	-5.25M -	-41.70M 695.02%	-346.07M 729.93%	-7.91M 97.71%	-82.06M 937.32%
net receivables				7.66M -	505K 93.40%
other assets
other current assets	514K -	1.89M 268.09%	2.60M 37.16%	4.44M 71.25%	3.29M 25.88%
other current liabilities	347K -	22.21M 6,300.29%	10.08M 54.61%	14.58M 44.64%	14.60M 0.14%
other liabilities
other non current assets		1.16M -	5.34M 358.59%	4.60M 13.90%	352K 92.34%
other non current liabilities			2.18M -	1.53M 29.55%	2.71M 76.97%
othertotal stockholders equity		404K -	105.24M 25,948.76%	503.70M 378.63%	547.86M 8.77%
preferred stock			366.33M -
property plant equipment net	1.33M -	4.62M 246.29%	12.32M 166.60%	61.91M 402.29%	62.61M 1.14%
retained earnings	-12.20M -	-48.08M 294.14%	-122.03M 153.83%	-230.54M 88.91%	-365.89M 58.71%
short term debt	750K -			3.13M -	3.16M 1.12%
short term investments				207.91M -	104.31M 49.83%
tax assets
tax payables
total assets	11.09M -	49.38M 345.09%	366.33M 641.89%	342.39M 6.54%	303.75M 11.28%
total current assets	9.76M -	43.59M 346.67%	348.67M 699.86%	275.89M 20.87%	236.21M 14.38%
total current liabilities	4.29M -	29.27M 582.08%	16.64M 43.17%	25.57M 53.68%	46.59M 82.22%
total debt	750K -			47.00M -	46.04M 2.05%
total investments				207.91M -	108.89M 47.63%
total liabilities	23.24M -	98.11M 322.11%	18.81M 80.82%	70.98M 277.25%	124.50M 75.42%
total liabilities and stockholders equity	11.09M -	49.38M 345.09%	366.33M 641.89%	342.39M 6.54%	303.75M 11.28%
total non current assets	1.33M -	5.79M 333.48%	17.66M 205.22%	66.50M 276.51%	67.54M 1.56%
total non current liabilities	18.95M -	68.83M 263.22%	2.18M 96.84%	45.41M 1,986.72%	77.91M 71.59%
total stockholders equity	-12.15M -	-48.73M 301.12%	347.51M 813.17%	271.41M 21.90%	179.25M 33.96%

COM:MONTEROSATX

Monte Rosa Therapeutics

Last Close

8.36

21/11 21:00

Market Cap

513.00M

Beta: -

Volume Today

741.95K

Avg: -

Preview